FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Moxifloxacin (Moxeza) Ophthalmic Solution
Status: Discontinuation
»Therapeutic Categories: Ophthalmology

Novartis (New 07/02/2021)

Company Contact Information:

Presentation Posting Date Related Information
5mg/mL, 3mL in 1 bottle, (NDC 0065-0006-03) 07/02/2021 Novartis Pharmaceuticals has made a business decision to permanently discontinue Moxeza (moxifloxacin hydrochloride) Solution 5mg/mL.

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English